Literature DB >> 32209444

Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms.

Wantong Song1, Manisit Das2, Xuesi Chen3.   

Abstract

With the rapid increase in the use of nanotechnology and immunotherapy for cancer management in the recent past, there are great implications for using nanotechnology in immuno-oncology. However, to deliver clinical success, the scientific and clinical rationale must be critically evaluated when applying nanotechnology to immuno-oncology challenges. This opinion article distinguishes between designing nanotherapeutics for immunotherapy and the past focus on the placement of chemotherapy agents in nanoparticles. We believe the integration of nanotechnology with cancer immunotherapy for nano-immunotherapeutics provides unique opportunities for both fields, paving the way for entirely new therapeutic paradigms. As a particular focus in our article, we envision the necessities and challenges of nanotechnology in the development of in situ cancer vaccines, immune checkpoint inhibitors, adoptive cell transfer, and bispecific antibody therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer; immunotherapy; nanotechnology

Mesh:

Substances:

Year:  2020        PMID: 32209444      PMCID: PMC7101275          DOI: 10.1016/j.trecan.2020.01.011

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  88 in total

Review 1.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

2.  Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.

Authors:  Yiran Zheng; Li Tang; Llian Mabardi; Sudha Kumari; Darrell J Irvine
Journal:  ACS Nano       Date:  2017-03-01       Impact factor: 15.881

3.  A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.

Authors:  Ning Cheng; Rebekah Watkins-Schulz; Robert D Junkins; Clément N David; Brandon M Johnson; Stephanie A Montgomery; Kevin J Peine; David B Darr; Hong Yuan; Karen P McKinnon; Qi Liu; Lei Miao; Leaf Huang; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  JCI Insight       Date:  2018-11-15

Review 4.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

5.  Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.

Authors:  Qi Liu; Hongda Zhu; Karthik Tiruthani; Limei Shen; Fengqian Chen; Keliang Gao; Xueqiong Zhang; Lin Hou; Degeng Wang; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2018-01-31       Impact factor: 15.881

Review 6.  Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.

Authors:  Thomas A Gardner; Bennett D Elzey; Noah M Hahn
Journal:  Hum Vaccin Immunother       Date:  2012-04       Impact factor: 3.452

Review 7.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

Review 8.  Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.

Authors:  Jin-Zhi Du; Hong-Jun Li; Jun Wang
Journal:  Acc Chem Res       Date:  2018-10-15       Impact factor: 22.384

9.  Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Authors:  Janos L Tanyi; Sara Bobisse; Eran Ophir; Sandra Tuyaerts; Annalisa Roberti; Raphael Genolet; Petra Baumgartner; Brian J Stevenson; Christian Iseli; Denarda Dangaj; Brian Czerniecki; Aikaterini Semilietof; Julien Racle; Alexandra Michel; Ioannis Xenarios; Cheryl Chiang; Dimitri S Monos; Drew A Torigian; Harvey L Nisenbaum; Olivier Michielin; Carl H June; Bruce L Levine; Daniel J Powell; David Gfeller; Rosemarie Mick; Urania Dafni; Vincent Zoete; Alexandre Harari; George Coukos; Lana E Kandalaft
Journal:  Sci Transl Med       Date:  2018-04-11       Impact factor: 17.956

10.  Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.

Authors:  Wantong Song; Limei Shen; Ying Wang; Qi Liu; Tyler J Goodwin; Jingjing Li; Olekasandra Dorosheva; Tianzhou Liu; Rihe Liu; Leaf Huang
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

View more
  5 in total

Review 1.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

Review 2.  Supramolecular Self-Assembled Nanostructures for Cancer Immunotherapy.

Authors:  Zichao Huang; Wantong Song; Xuesi Chen
Journal:  Front Chem       Date:  2020-05-25       Impact factor: 5.221

3.  Extracellular Vesicles from Akkermansia muciniphila Elicit Antitumor Immunity Against Prostate Cancer via Modulation of CD8+ T Cells and Macrophages.

Authors:  Zhong-Wei Luo; Kun Xia; Yi-Wei Liu; Jiang-Hua Liu; Shan-Shan Rao; Xiong-Ke Hu; Chun-Yuan Chen; Ran Xu; Zhen-Xing Wang; Hui Xie
Journal:  Int J Nanomedicine       Date:  2021-04-20

Review 4.  Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.

Authors:  Abdulaziz B Hamid; Ruben C Petreaca
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

Review 5.  Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.

Authors:  Chang Yang; Bai-Rong Xia; Zhao-Cong Zhang; Yong-Jian Zhang; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.